2026-03-05T08:00:10Z https://tokushima-u.repo.nii.ac.jp/oai

oai:tokushima-u.repo.nii.ac.jp:02013296 2025-06-11T08:06:17Z 1713829974766:1713854681789:1745467575633:1745467619908 1713853213384:1713853295607

Melanoma antigen is a vaccine candidate antigen Melanoma antigen is a vaccine candidate against Meth A sarcoma 中本, 晶子 863 ナカモト, アキコ 323760/profile-ja.html Nakamoto, Akiko 90803536 Ohashi, Haruka Tanaka, Yuko Yamamoto, Mako 中本, 真理子 782 ナカモト, マリコ 293911/profile-ja.html Nakamoto, Mariko 40722533 首藤, 恵泉 324 シュトウ, エミ 10512121 Shuto, Emi 酒井, 徹 1196 サカイ, トオル 60693/profile-ja.html Sakai, Tohru 40274196 Meth A CD8+ cells melanoma antigen vaccine Sarcoma Meth A is widely used in the field of immunology and oncology study. We found that a mutant cell line, Meth A (mMeth A), was rejected in an in vivo subcutaneous challenge in BALB / c mice. mMeth A cells were not rejected in athymic BALB / c-nu / nu mice and CD8+ cell-depleted BALB / c mice, suggesting that CD8+ cells are required for rejection of mMeth A cells. Microarray analysis showed that melanoma antigen (MAg) was one of the most elevated genes in mMeth A cells. Indeed, quantitative gene expression analysis showed that the expression level of MAg in mMeth A cells was one hundred-times higher than that in Meth A cells. We constructed two types of expression vector coding the MAg gene sequence corresponding to 788–1257 and 1611-2043 and immunized mice with these genes by intramuscular injection. Immunization of a plasmid expressing the Mag 788-1257 gene protected the mice from in vivo Meth A challenge as evaluated by tumor volume and survival rate. The results reveal that MAg is a potential vaccine candidate antigen against Meth A tumors. journal article Tokushima University Faculty of Medicine 2025-02 VoR application/pdf The Journal of Medical Investigation 1-2 72 161 166 13496867 13431420 AA11166929 https://tokushima-u.repo.nii.ac.jp/record/2013296/files/jmi_72_1-2_161.pdf https://tokushima-u.repo.nii.ac.jp/records/2013296 eng